Loading…
Employees: 2,843
Size Sihuan Pharmaceutical (0460.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $952M, the 603rd largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$0.80 on 6 Nov 2026.
Performance Over six months the shares fell 35.5%, against -16.5% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 29.7% over the last twelve months (peer median +3.1%); the operating margin is 14.5% (peer median 10.9%).
Valuation It trades at 9.7× forward earnings against a peer median of 26.9× (2nd cheapest of 15).
Capital Return on invested capital runs 3.4 points below its cost of capital (8.2% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.94B | HK$2.84B | HK$2.06B | HK$2.06B | HK$2.54B |
| Revenue growth | — | +38% | 0% | -19% | — |
| Gross profit | HK$1.92B | HK$1.90B | HK$1.27B | HK$1.35B | HK$1.62B |
| EBITDA | HK$662M | HK$658M | -HK$175M | HK$26.2M | -HK$129M |
| Net income | HK$341M | HK$195M | -HK$235M | -HK$59.7M | -HK$2.27B |
| Free cash flow | -HK$108M | -HK$47.3M | HK$301M | HK$199M | -HK$306M |
| Capital expenditure | HK$265M | HK$211M | HK$202M | HK$326M | HK$691M |
| Total debt | n/a | HK$1.12B | HK$1.04B | HK$1.40B | HK$1.47B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0460.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.9% | -5.5% | highest of 21 |
| 6-month return | -35.5% | -16.5% | 3rd lowest of 21 |
| Distance from 52-week high | -55.3% | -34.9% | 2nd lowest of 21 |
| Revenue growth (TTM) | +29.7% | +3.1% | 4th highest of 20 |
| Operating margin | 14.5% | 10.9% | 9th highest of 19 |
| Forward P/E | 9.7× | 26.9× | 2nd cheapest of 15 |
| ROIC minus cost of capital | -3.4 pp | +1.4 pp | 5th lowest of 19 |
| EV / EBITDA | 10.4× | 21.4× | cheapest of 8 |
| Net debt / EBITDA | -2.3× | -1.1× | 4th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.09B | -10% | -5% | 4% | 18.3× | 1.5% | +7.9% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | n/a | 1.8% | +4.8% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | 7.2× | n/a | n/a |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | n/a | 4.9% | +13.5% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | n/a | n/a | n/a |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | n/a | n/a | n/a |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 438.0× | n/a | n/a |